Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: A report of two cases

Joint Bone Spine

Volumn 76, Issue 2, 2009, Pages 190-194

  Singh, Jasvinder A ^a   Mahowald, Maren L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Botulinum toxin; Intra articular injection; Refractory joint pain; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BOTULINUM TOXIN A; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADJUVANT THERAPY; ADULT; ANKLE; ARTHRALGIA; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; FOOT; HEARTBURN; HUMAN; JOINT SWELLING; MALE; MONARTHRITIS; RASH; RHEUMATOID ARTHRITIS; TREATMENT FAILURE;

ADJUVANTS, PHARMACEUTIC; ANKLE JOINT; ANTI-DYSKINESIA AGENTS; ARTHRITIS, RHEUMATOID; BOTULINUM TOXIN TYPE A; HEALTH STATUS; HUMANS; INJECTIONS, INTRA-ARTICULAR; MALE; METATARSOPHALANGEAL JOINT; MIDDLE AGED; PAIN; PAIN MEASUREMENT; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 61449121167     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2008.05.006     Document Type: Article

References (21)

1. Fisher B.A., and Keat A. Should we be using intraarticular tumor necrosis factor blockade in inflammatory monoarthritis?. J Rheumatol 33 (2006) 1934-1935
2. Hokfelt T., Kellerth J.O., Nilsson G., et al. Substance p: localization in the central nervous system and in some primary sensory neurons. Science 190 (1975) 889-890
3. Saxler G., Loer F., Skumavc M., et al. Localization of SP- and CGRP-immunopositive nerve fibers in the hip joint of patients with painful osteoarthritis and of patients with painless failed total hip arthroplasties. Eur J Pain 11 (2007) 67-74
4. Heppelmann B., and Pawlak M. Sensitisation of articular afferents in normal and inflamed knee joints by substance P in the rat. Neurosci Lett 223 (1997) 97-100
5. Hanesch U., Pfrommer U., Grubb B.D., et al. The proportion of CGRP-immunoreactive and SP-mRNA containing dorsal root ganglion cells is increased by a unilateral inflammation of the ankle joint of the rat. Regul Pept 46 (1993) 202-203
6. Jancso N., Jancso-Gabor A., and Szolcsanyi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother 31 (1967) 138-151
7. Lembeck F., and Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 310 (1979) 175-183
8. Colpaert F.C., Donnerer J., and Lembeck F. Effects of capsaicin on inflammation and on the substance P content of nervous tissues in rats with adjuvant arthritis. Life Sci 32 (1983) 1827-1834
9. Lam F.Y., and Ferrell W.R. Inhibition of carrageenan induced inflammation in the rat knee joint by substance P antagonist. Ann Rheum Dis 48 (1989) 928-932
10. Foreman J.C., Jordan C.C., and Piotrowski W. Interaction of neurotensin with the substance P receptor mediating histamine release from rat mast cells and the flare in human skin. Br J Pharmacol 77 (1982) 531-539
11. Schaible H.G., Ebersberger A., and Von Banchet G.S. Mechanisms of pain in arthritis. Ann N Y Acad Sci 966 (2002) 343-354
12. Simpson L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 33 (1981) 155-188
13. Cui M., Li Z., You S., et al. Mechanisms of the antinociceptive effect of subcutaneous Botox: inhibition of peripheral and central nociceptive processing. Arch Pharm 365 Suppl. 2 (2002) R17
14. Purkiss J., Welch M., Doward S., et al. Capsicin stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 59 (2000) 1403-1406
15. Jankovic J., and Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 40 (1990) 277-280
16. Bertolini D.R., Nedwin G.E., Bringman T.S., et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319 (1986) 516-518
17. Gobel H., Heinze A., Heinze-Kuhn K., et al. Evidence based medicine: botulinum toxin A in migraine and tension type headache. J Neurol 248 Suppl. (2001) 34-38
18. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 85 (2000) 101-105
19. Keizer S., Rutten H., Pilot P., et al. Botulinum toxin injection versus surgical treatment for tennis elbow: a randomized pilot study. Clin Orthop 401 (2002) 125-131
20. Mahowald M.L., Singh J.A., and Dykstra D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res 9 (2006) 179-188
21. DePuy T., Howard R., Keegan K., et al. Effects of intra-articular botulinum toxin type A in an equine model of acute synovitis: a pilot study. Am J Phys Med Rehabil 86 (2007) 777-783